These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29054331)

  • 1. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases.
    Pereira R; Raposo I; Nery F; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):285-287. PubMed ID: 29054331
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
    Sanz-Bueno J; Vanaclocha F; García-Doval I; Torrado R; Carretero G; Daudén E; Patricia Ruiz-Genao D; Alsina-Gibert MM; Pérez-Zafrilla B; Pérez-Rial G; Rivera R;
    Actas Dermosifiliogr; 2015; 106(6):477-82. PubMed ID: 25776200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
    Cho YT; Chen CH; Chiu HY; Tsai TF
    J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus.
    Giannitti C; Sebastiani GD; Manganelli S; Galeazzi M
    J Rheumatol; 2011 Apr; 38(4):780-1. PubMed ID: 21459960
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
    Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
    J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vital hepatitis reactivation with anti-tumor necrosis factor-alpha: what do we know?
    Zuckerman E
    Isr Med Assoc J; 2013 Jun; 15(6):298-300. PubMed ID: 23882896
    [No Abstract]   [Full Text] [Related]  

  • 11. Gastroenterologists Have Suboptimal Hepatitis B Virus Screening Rates in Patients Receiving Immunosuppressive Therapy.
    Paul S; Shuja A; Tam I; Kim EM; Kang S; Kapulsky L; Viveiros K; Lee H
    Dig Dis Sci; 2016 Aug; 61(8):2236-2241. PubMed ID: 26993822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis.
    Navarro R; Concha-Garzón MJ; Castaño C; Casal C; Guiu A; Daudén E
    Int J Dermatol; 2014 Jul; 53(7):909-11. PubMed ID: 24673290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis.
    Moghoofei M; Mostafaei S; Ashraf-Ganjouei A; Kavosi H; Mahmoudi M
    Microb Pathog; 2018 Jan; 114():436-443. PubMed ID: 29223453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
    Piaserico S; Messina F; Russo FP
    Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations.
    Fuchs I; Abu-Shakra M; Sikuler E
    Isr Med Assoc J; 2013 Jun; 15(6):303-7. PubMed ID: 23882898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching TNFα inhibitors: Patterns and determinants.
    Meijboom RW; Gardarsdottir H; Becker ML; de Groot MCH; Movig KLL; Kuijvenhoven J; Egberts TCG; Leufkens HGM; Giezen TJ
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00843. PubMed ID: 34302442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis.
    Manalo IF; Gilbert KE; Wu JJ
    J Am Acad Dermatol; 2015 Nov; 73(5):881-2. PubMed ID: 26475547
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.
    Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.
    Ting SW; Chen YC; Huang YH
    Clin Drug Investig; 2018 Sep; 38(9):873-880. PubMed ID: 29968197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.